会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY
    • EP4285998A2
    • 2023-12-06
    • EP23182534.0
    • 2015-04-07
    • The University of Nottingham
    • BOTLEY, AndrewHAYES, ChristopherSEYMOUR, GrahamGRABAWSKA, AnnaCLARKE, Philip
    • A61P21/00
    • A compound of Formula I:

               R1-L1-C(A)(A') - CH 2 - L2-R2     (I)

      or a pharmaceutically acceptable salt thereof,
      for use in medicine, for example in the treatment of a disease or condition selected from the group comprising cancer, autistic spectrum disorders, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, muscle wasting and viral infection,
      wherein:
      R1 is selected from a carbohydrate group or derivative thereof, hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group;
      L1 is a linking group;
      L2 is a linking group;
      R2 is selected from hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group;
      A is selected from hydrogen and a C1-C6 alkyl group;
      A' is selected from hydrogen, a C1-C6 alkyl group, and L3-R3; wherein
      L3 is a linking group; and
      R3 is selected from hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group;
      and wherein if A' is not L3-R3, then R2 is a C10-C24 alkyl or a C10-C24 derivative of an alkyl group, a C10-C24 alkenyl or a C10-C24 derivative of an alkenyl group, or a C10-C24 alkynyl group or a C10-C24 derivative of an alkynyl group;
      and wherein if A' is L3-R3, then one or both of R2 and R3 are a C10-C24 alkyl or a C10-C24 derivative of an alkyl group, a C10-C24 alkenyl or a C10-C24 derivative of an alkenyl group, or a C10-C24 alkynyl group or a C10-C24 derivative of an alkynyl group.
    • 2. 发明公开
    • GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY
    • EP4285998A3
    • 2024-02-14
    • EP23182534.0
    • 2015-04-07
    • The University of Nottingham
    • BOTLEY, AndrewHAYES, ChristopherSEYMOUR, GrahamGRABAWSKA, AnnaCLARKE, Philip
    • A61K31/7024A61K45/06A61K31/7032A61K33/24C07H3/02A61P35/00A61P25/16A61P25/28A61P25/00A61P31/12A61P21/00
    • A compound of Formula I:

               R1-L1-C(A)(A') - CH 2 - L2-R2     (I)

      or a pharmaceutically acceptable salt thereof,
      for use in medicine, for example in the treatment of a disease or condition selected from the group comprising cancer, autistic spectrum disorders, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, muscle wasting and viral infection,
      wherein:
      R1 is selected from a carbohydrate group or derivative thereof, hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group;
      L1 is a linking group;
      L2 is a linking group;
      R2 is selected from hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group;
      A is selected from hydrogen and a C1-C6 alkyl group;
      A' is selected from hydrogen, a C1-C6 alkyl group, and L3-R3; wherein
      L3 is a linking group; and
      R3 is selected from hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group;
      and wherein if A' is not L3-R3, then R2 is a C10-C24 alkyl or a C10-C24 derivative of an alkyl group, a C10-C24 alkenyl or a C10-C24 derivative of an alkenyl group, or a C10-C24 alkynyl group or a C10-C24 derivative of an alkynyl group;
      and wherein if A' is L3-R3, then one or both of R2 and R3 are a C10-C24 alkyl or a C10-C24 derivative of an alkyl group, a C10-C24 alkenyl or a C10-C24 derivative of an alkenyl group, or a C10-C24 alkynyl group or a C10-C24 derivative of an alkynyl group.
    • 3. 发明公开
    • GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY
    • GLYKOLIPIDE UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DARAUS ZUR VERWENDUNG IN DER THERAPIE
    • EP3129057A1
    • 2017-02-15
    • EP15717051.5
    • 2015-04-07
    • The University Of Nottingham
    • BOTTLEY, AndrewHAYES, ChristopherSEYMOUR, GrahamGRABAWSKA, AnnaCLARKE, Philip
    • A61K45/06A61K31/7032A61K33/24C07H3/02A61P35/00A61P25/16A61P25/28A61P25/00A61P31/12A61P21/00
    • C07H15/06A23L33/16A23L33/30A23V2002/00A61K31/7032A61K33/24A61K45/06A61K2300/00
    • A compound of Formula I: R1 -L1 -C(A)(A') - CH
      2 , - L2-R2 or a pharmaceutically acceptable salt thereof, for use in medicine, for example in the treatment of a disease or condition selected from the group comprising cancer, autistic spectrum disorders. Alzheimer' s disease, Parkinson's disease, Huntingdon' s disease, muscie wasting and viral infection, wherein: R1 is selected from a carbohydrate group or derivative thereof, hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an aikenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group; L1 is a linking group; L2 is a linking group; R2 is selected from hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group; A is selected from hydrogen and a C1 -C6 alkyl group: A' is selected from hydrogen, a C3 -C6 alkyl group, and L3-R3; wherein L3 is a linking group; and R3 is selected from hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group; and wherein if A' is not L3-R3, then R2 is a C10-C24 alkyl or a C10-C24 derivative of an alkyl group, a C10-C24 alkenyl or a C10-C24 derivative of an alkenyl group, or a C10-C24 alkynyl group or a C10-C24 derivative of an alkynyl group; and wherein if A' is L3-R3, then one or both of R2 and R3 are a C10-C24 alkyl or a C10-C24 derivative of an alkyl group, a C10-C24 alkenyl or a C10-C24 derivative of an alkenyl group, or a C10-C24 alkynyl group or a C10-C24 derivative of an alkynyl group.
    • 式I的化合物:R 1 -L 1 -C(A)(A')-CH 2,-L 2 -R 2或其药学上可接受的盐,用于医学中,例如用于治疗选自以下的疾病或病症: 组包括癌症,自闭症谱系障碍。 阿尔茨海默氏病,帕金森病,亨廷顿氏病,肌肉消瘦和病毒感染,其中:R1选自碳水化合物基团或其衍生物,氢,烷基的C 1 -C 24烷基或C 1 -C 24衍生物, 链烯基的C2-C24链烯基或C2-C24衍生物,炔基的C2-C24炔基或C2-C24衍生物; L1是连接基团; L2是连接基团; R2选自氢,C 1 -C 24烷基或C 1 -C 24衍生物,C 2 -C 24链烯基或链烯基的C 2 -C 24衍生物,以及C 2 -C 24炔基或C 2 -C 24 炔基的衍生物; A选自氢和C 1 -C 6烷基:A'选自氢,C 3 -C 6烷基和L 3 -R 3; 其中L3是连接基团; 并且R 3选自氢,C 1 -C 24烷基或C 1 -C 24衍生物的烷基,C 2 -C 24烯基或C 2 -C 24衍生物的烯基,以及C 2 -C 24炔基或C 2 -C 24炔基, 炔基的C24衍生物; 并且其中如果A'不是L3-R3,那么R 2是烷基的C 10 -C 24烷基或C 10 -C 24衍生物,链烯基的C 10 -C 24烯基或C 10 -C 24衍生物或C10- C24炔基或炔基的C10-C24衍生物; 并且其中如果A'是L3-R3,那么R 2和R 3中的一个或两个是C 1 -C 24烷基或C 1 -C 24烷基的C 10 -C 24衍生物,链烯基的C 10 -C 24烯基或C 10 -C 24衍生物 ,或C10-C24炔基或炔基的C10-C24衍生物。